{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:33:45Z","timestamp":1768527225916,"version":"3.49.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Discuss the importance of treating patients with bone metastases using a multidisciplinary approach.Explain why bisphosphonates are a fundamental part of bone metastasis treatment.Evaluate the main features of ONJ and, in particular, its high risk factor.Describe the importance of ONJ prevention during bisphosphonate treatment.Emphasize the importance of interaction among the patient's dentist, surgeon, and oncologist for the management of ONJ.<\/jats:p>\n                  <jats:p>CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit\u2122 at CME.TheOncologist.com<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective.<\/jats:title>\n                  <jats:p>Bone metastases are a major cause of morbidity in cancer patients. Treatment includes bisphosphonates, which are also associated with avascular osteonecrosis of the jaw (ONJ). Our aim was to evaluate the correlation between bisphosphonates and ONJ.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>Of the 539 patients with bone metastases treated in our department from June 2002 to December 2006 with i.v. bisphosphonates, eight (1.5%) developed ONJ.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>The eight patients with ONJ had all been given zoledronic acid, and two had also been treated with pamidronic acid. In four of the patients, ONJ was diagnosed during treatment, while in the remaining four it was diagnosed several months after therapy with bisphosphonates had ended. Six of these patients received local noninvasive treatment, of whom five progressed. Two showed apparent autolimitation of the disease. The remaining two patients underwent surgical resection and currently show no signs of relapse. All eight ONJ patients presented with various concomitant risk factors such as paradontopathy, dental extraction, or spontaneous avulsion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>Our results show that ONJ can appear months after interruption of treatment and that a surgical approach can be used in suitable cases. Closer cooperation is needed among specialists to define guidelines for the prevention of ONJ in patients with bone metastases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2007-0159","type":"journal-article","created":{"date-parts":[[2008,3,31]],"date-time":"2008-03-31T12:43:00Z","timestamp":1206967380000},"page":"330-336","source":"Crossref","is-referenced-by-count":49,"title":["Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study"],"prefix":"10.1093","volume":"13","author":[{"given":"Toni","family":"Ibrahim","sequence":"first","affiliation":[{"name":"a Osteo-oncology Center and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Barbanti","sequence":"additional","affiliation":[{"name":"b Oral Surgery and Dentistry Department, Otorhinolaryngology Unit, Morgagni Pierantoni Hospital, Forl\u00ec, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Giorgio-Marrano","sequence":"additional","affiliation":[{"name":"b Oral Surgery and Dentistry Department, Otorhinolaryngology Unit, Morgagni Pierantoni Hospital, Forl\u00ec, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mercatali","sequence":"additional","affiliation":[{"name":"a Osteo-oncology Center and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Ronconi","sequence":"additional","affiliation":[{"name":"a Osteo-oncology Center and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Vicini","sequence":"additional","affiliation":[{"name":"b Oral Surgery and Dentistry Department, Otorhinolaryngology Unit, Morgagni Pierantoni Hospital, Forl\u00ec, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dino","family":"Amadori","sequence":"additional","affiliation":[{"name":"a Osteo-oncology Center and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,3,1]]},"reference":[{"issue":"Suppl","key":"2021122208161921800_R1","first-page":"29","article-title":"Clinical epidemiology and specific cancer therapy of bone metastases from solid tumors","volume":"2","author":"Ibrahim","year":"2006","journal-title":"Supportive Palliative Cancer Care"},{"key":"2021122208161921800_R2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"2021122208161921800_R3","first-page":"59","volume-title":"Clinica e complicanze delle metastasi ossee in osteoncologia, un approccio multidisciplinare","author":"Amadori","year":"2003"},{"key":"2021122208161921800_R4","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and its effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"2021122208161921800_R5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"2021122208161921800_R6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3816\/CGC.2005.n.009","article-title":"Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer","volume":"4","author":"Saad","year":"2005","journal-title":"Clin Prostate Cancer"},{"key":"2021122208161921800_R7","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208161921800_R8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122208161921800_R9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systemic review: Bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"2021122208161921800_R10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122208161921800_R11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1054\/ijom.2002.0332","article-title":"Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients\u2014a report of a thirty year retrospective review","volume":"32","author":"Reuther","year":"2003","journal-title":"Int J Oral Maxillofac Surg"},{"key":"2021122208161921800_R12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis and treatment of ONJ in patient with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J Oncol Pract"},{"key":"2021122208161921800_R13","first-page":"397","article-title":"[Osteoradionecrosis. I. Etiology, pathogenesis, clinical aspects and risk factors.]","volume":"30","author":"Thiel","year":"1989","journal-title":"Radiobiol Radiother (Berl)"},{"key":"2021122208161921800_R14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.joms.2003.08.009","article-title":"Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patients","volume":"62","author":"Oh","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122208161921800_R15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.joms.2003.11.003","article-title":"Bisphosphonates and bone necrosis","volume":"62","author":"Pogrel","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122208161921800_R16","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122208161921800_R17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/13543784.14.1.45","article-title":"Thalidomide and iummunomodulatory drugs in the treatment of cancer","volume":"14","author":"Bamias","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122208161921800_R18","volume-title":"Novartis Oncology [letter]","author":"U.S. Food and Drug Administration MedWatch","year":"2006"},{"key":"2021122208161921800_R19","author":"U.S. Food and Drug Administration MedWatch","year":"2006"},{"key":"2021122208161921800_R20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122208161921800_R21","first-page":"621","article-title":"Novel approaches of the management of myeloma","volume":"19","author":"Rajkumar","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"2021122208161921800_R22","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208161921800_R23","first-page":"190a","article-title":"Osteonecrosis of the jaws in myeloma: Analysis of risk factors including time dependency of Aredia and Zometa use, steroid use and underlying dental problems","volume":"90","author":"Durie","year":"2005","journal-title":"Haematologica"},{"key":"2021122208161921800_R24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdl408","article-title":"Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis","volume":"18","author":"Aguiar Bujanda","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122208161921800_R25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl","key":"2021122208161921800_R26","doi-asserted-by":"crossref","first-page":"8528a","DOI":"10.1200\/jco.2006.24.18_suppl.8528","article-title":"Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy","volume":"24","author":"Hoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208161921800_R27","article-title":"Expert panel recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaws","volume-title":"Dockets Management, US Food and Drug Administration","author":"Damato","year":"2007"},{"key":"2021122208161921800_R28","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","article-title":"Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years","volume":"10","author":"Guarneri","year":"2005","journal-title":"The Oncologist"},{"key":"2021122208161921800_R29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"2021122208161921800_R30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: A clinical pharmacological and pharmacokinetic update","volume":"44","author":"Barrett","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"2021122208161921800_R31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"2021122208161921800_R32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208161921800_R33","first-page":"116","volume-title":"Metastasi ossee: Approccio multidisciplinare","author":"Ibrahim","year":"2007"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2007-0159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2007-0159","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/3\/330\/41831733\/oncolo_13_3_330.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/3\/330\/41831733\/oncolo_13_3_330.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T13:26:43Z","timestamp":1640179603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/13\/3\/330\/6396612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,3,1]]},"published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2007-0159","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,3,1]]},"published":{"date-parts":[[2008,3,1]]}}}